Neurocrine Biosciences (STU:NB3) Retained Earnings: €628 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NB3 Neurocrine Biosciences Inc STU:NB3
90 GF Score
Price €138.60
GF Value €169.34
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Retained Earnings?

Neurocrine Biosciences STU:NB3 -0.93% 90 Retained Earnings is €628 Mil as of Jun. 2026. GuruFocus rates STU:NB3 with a GF Score™ of 90/100 and a GF Value™ of €169.34 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Neurocrine Biosciences's retained earnings for the quarter that ended in Jun. 2026 was €628 Mil.

Neurocrine Biosciences's quarterly retained earnings increased from Dec. 2025 (€382 Mil) to Mar. 2026 (€510 Mil) and increased from Mar. 2026 (€510 Mil) to Jun. 2026 (€628 Mil).

Neurocrine Biosciences's annual retained earnings increased from Dec. 2023 (€-144 Mil) to Dec. 2024 (€28 Mil) and increased from Dec. 2024 (€28 Mil) to Dec. 2025 (€382 Mil).


Neurocrine Biosciences  (STU:NB3) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Neurocrine Biosciences Retained Earnings Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Retained Earnings Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -562.68 -384.02 -144.06 27.89 382.34

Neurocrine Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.26 250.49 382.34 510.00 628.43
STU:NB3
90GF Score
Neurocrine Biosciences Inc STU:NB3
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €628 Mil mean?
Neurocrine Biosciences (STU:NB3) has a Retained Earnings of €628 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Retained Earnings too high?
Neurocrine Biosciences' current Retained Earnings is €628 Mil. Overall, Neurocrine Biosciences has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Retained Earnings compare to VTRS and UTHR?
Neurocrine Biosciences' Retained Earnings of €628 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Retained Earnings is €628 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (STU:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €169.34, compared to a current price of €138.60 — trading 18.2% below its estimated fair value. The current Retained Earnings is €628 Mil. Neurocrine Biosciences' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Neurocrine Biosciences (STU:NB3), the current Retained Earnings is €628 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (STU:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €138.60 is trading 18.2% below its estimated GF Value™ of €169.34. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for STU:NB3:

  • Retained Earnings: €628 Mil
  • GF Value™: €169.34 vs. price of €138.60 (18.2% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the STU:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
90GF Score

Get the complete analysis for STU:NB3

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€138.60
Price
€169.34
GF Value